Ribociclib Succinate

琥珀酸瑞波西利

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameRibociclib Succinate
Drug Alias Nameribociclibum瑞波西利利波西利Ribociclib琥珀酸瑞博西尼 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsBone metastasesPancreatic neuroendocrine tumors (pNET)Metastatic breast cancer +[46] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2017/03/13
Country/TerritoryCzechiaBelgiumBulgaria +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesOhsu Knight Cancer InstituteNovartis Pharma Schweiz AgH Lee Moffitt Cancer Center & Research Institute +[12] 
Inactive CompaniesDana-Farber Cancer InstituteUniversity of Texas Southwestern Medical CenterRoswell Park Cancer Institute +[10] 
Active IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[20] 
Inactive IndicationsBone metastasesPancreatic neuroendocrine tumors (pNET)Neuroendocrine Carcinoma of Lung +[26] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG